Year Founded
2019
Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Small molecule

Ventus Therapeutics General Information

Lead program VENT-02 (brain-penetrant NLRP3 inhibitor) in Phase 2 for Parkinson's disease. VENT-03 (cGAS inhibitor) expected to enter Phase 2 for lupus in 2025.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Waltham, Massachusetts
USA

Drug Pipeline

VENT-02
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Ventus Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Ventus Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Ventus Therapeutics's complete valuation and funding history, request access »

Ventus Therapeutics Investors

Versant Ventures (founding investor)
Investor Type: Venture Capital
Holding: Minority
GV (formerly Google Ventures)
Investor Type: Venture Capital
Holding: Minority
others not specified.[5]
Investor Type: Venture Capital
Holding: Minority